Edition:
India

Profile: Sierra Oncology Inc (SRRA.OQ)

SRRA.OQ on NASDAQ Stock Exchange Global Market

10.95USD
28 Sep 2020
Change (% chg)

-- (--)
Prev Close
$10.95
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
5,526
52-wk High
$21.60
52-wk Low
$8.62

Sierra Oncology, Inc., incorporated on May 8, 2003, is late stage drug development company. The Company is focused on advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Momelotinib, the Company’s lead drug candidate, is a potent, selective and orally-bioavailable janus kinase one (JAK1), janus kinase two (JAK2) and activin a receptor type one (ACVR1) inhibitor with a differentiated therapeutic profile in myelofibrosis.

The Company is also developing a portfolio of deoxyribonucleic acid (DNA) damage response (DDR) assets, consisting of SRA737 and SRA141. SRA737 is a potent, selective, orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of cell cycle progression and the DDR network. SRA141 is a potent, selective, orally bioavailable small molecule inhibitor of Cell division cycle 7 kinase (Cdc7).

Company Address

Sierra Oncology Inc

2150 ? 885 West Georgia Street
VANCOUVER   BC   V6C 3E8
P: +1604.5586536
F: +1302.6365454

Company Web Links